What is the current share price of Onesource Specialty Pharma Limited (ONESOURCE)?

As of the latest market update, Onesource Specialty Pharma Limited (ONESOURCE) is trading at ₹1,612.5. The stock has moved 2.36% down in the recent session.

What is the technical sentiment for ONESOURCE stock?

Based on our proprietary technical analysis, the current signal for ONESOURCE is "STRONG_SELL". This analysis considers over 20+ indicators including RSI, MACD, and moving average crossovers to gauge market momentum.

What is the 52-week high and low for Onesource Specialty Pharma Limited?

Onesource Specialty Pharma Limited has seen a 52-week high of ₹2,248 and a 52-week low of ₹1,057. Comparing the current price to these levels helps investors understand the stock's relative valuation and volatility over the past year.

Which sector does Onesource Specialty Pharma Limited belong to?

Onesource Specialty Pharma Limited operates in the Healthcare sector, specifically within the Pharmaceuticals & Biotechnology industry. Its performance is often influenced by broader trends in the Healthcare segment.

What is the market capitalization of ONESOURCE?

Onesource Specialty Pharma Limited (ONESOURCE) has a market capitalization of approximately ₹18.48K Cr. This classifies it as a small cap stock in the Indian market.

ONESOURCE

NSE

Onesource Specialty Pharma Limited (SMALL CAP)

Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals

₹1,612.50

38.90 (2.36%)

High VOLATILITY

As on 12 Jun 2026

Advanced Chart

Price History

Market Cap

The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.

₹18.48K Cr

SMALL CAP

P/E Ratio

Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.

1023.9

Industry

The specific business sector the company operates in. Useful for comparing with similar companies.

Pharmaceuticals

52-Week Range

The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.

52W Low₹1,057+52.6%

52W High₹2,248-28.3%

Current Price

₹1,612.50

Circuit Limits (20%)

The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.

Lower Circuit₹1,290.00

Upper Circuit₹1,935.00

Reference Price

₹1,612.50

Investment Checklist

Triple Top on 1W (BREAKOUT CONFIRMED) — target ₹1437.8

Double Top on 1W (BREAKOUT CONFIRMED) — target ₹1440.9

Composite score -61.41 (STRONG_SELL) with 87.5% confidence

Trend: Price below most MAs — downtrend | Bullish MA stack (20>50>200)

News: Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift...

Technical Analysis

Analysis from 2026-06-12

Confidence

88%

Trend

BEARISH

Price below most MAs — downtrend | Bullish MA stack (20>50>200)

EMA20

1753.23

EMA50

1705.23

EMA200

1704.66

Price Action

DOWNTREND

BEARISH

Higher Highs1

Higher Lows2

Lower Highs8

Lower Lows7

Support & Resistance Levels

Resistance (Above)

₹1681.40

₹1705.27

₹1799.33

₹1863.73

₹1907.66

Support (Below)

₹1583.60

₹1540.73

₹1492.35

₹1395.40

₹1316.40

Volume Analysis

TrendSTABLE

Change-6.60%

Unusual VolumeNo

Stop Loss Levels

Fixed Risk

1% Risk₹1596.38

3% Risk₹1564.13

5% Risk₹1531.88

7% Risk (Custom)

₹1499.63

Technical Levels

1x ATR (Volatility)₹1539.32

2x ATR (Swing)₹1466.14

3x ATR (Trend)₹1392.96

Immediate Support₹1583.60

Financials

Financial Analysis

Metric	Mar '25	Jun '25	Sep '25	Dec '25
Revenue	₹426 Cr	₹327.3 Cr	₹375.8 Cr	₹290.3 Cr
Net Profit	₹98.5 Cr	₹-18,60,000	₹10.5 Cr	₹-88.7 Cr
EPS	—	₹-0.02	₹0.92	₹-7.74
Operating Profit	₹173.2 Cr	₹90.9 Cr	₹109.5 Cr	₹14.9 Cr

ROE

-0.31%

ROCE

1.28%

Debt/Equity

0.16

Current Ratio

0.98

OPM

5.12%

NPM

-30.55%

Peer Comparison

Pharmaceuticals

Peer Comparison

Symbol	Name	Price	Change
SUNPHARMA	Sun Pharmaceutical Industries Limited	₹1,807.70	+0.75%
DIVISLAB	Divi's Laboratories Limited	₹6,638.00	-0.26%
TORNTPHARM	Torrent Pharmaceuticals Limited	₹4,571.20	-0.02%
CIPLA	Cipla Limited	₹1,389.40	+0.44%
ZYDUSLIFE	Zydus Lifesciences Limited	₹1,104.70	-0.11%
DRREDDY	Dr. Reddy's Laboratories Limited	₹1,275.40	-0.05%
LUPIN	Lupin Limited	₹2,293.30	+0.88%
MANKIND	Mankind Pharma Limited	₹2,381.10	+0.35%
AUROPHARMA	Aurobindo Pharma Limited	₹1,472.80	+0.59%
LAURUSLABS	Laurus Labs Limited	₹1,394.30	+0.25%

Corporate Information

Large Deals

View All

Bulk, Block and Short deals reported for this stock.

Loading Deals...

Announcements

Latest updates

View All

Date	Description	Link
20 May 2026	Analysts/Institutional Investor Meet/Con. Call Updates
19 May 2026	Updates
19 May 2026	Updates
16 May 2026	Updates
15 May 2026	Copy of Newspaper Publication

Board Meetings

Upcoming and past meetings

View All

Date	Purpose	Links
13 May 2026	Board Meeting Intimation	XBRL
13 May 2026	Financial Results
23 Jan 2026	Board Meeting Intimation	XBRL
23 Jan 2026	Financial Results
11 Nov 2025	Financial Results

Corporate Events

Upcoming results & meetings

View All

No upcoming events found

We couldn't find any scheduled corporate actions for this symbol at the moment.

Shareholding Pattern

As of Dec 2025Pledged: 18.52%

Current Distribution

Trend (Last 5 Qtrs)

Latest News

News for ONESOURCE

View All

Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift

positive

CNBC TV18 - Markets 3d ago

Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift

Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.

ABSLNN50ETBIOCONBSLGOLDETFHCGHCG-REHEALTHCAREHEALTHYLUPINMANKINDONESOURCESPARCFinancial ServicesHealthcare

Read full story

AI-led global earnings pressure India; opportunities in power, pharma: Conrad Saldanha

positive

CNBC TV18 - Markets 4d ago

AI-led global earnings pressure India; opportunities in power, pharma: Conrad Saldanha

Neuberger Berman MD & Portfolio Manager Conrad Saldanha discusses why AI-driven earnings growth in the US, Korea and Taiwan continues to attract capital, shares his outlook on India, and highlights opportunities in power infrastructure, airports, specialty pharma and select financials.

AKCAPITCPCAPGLOBALGVPILONESOURCECapital GoodsConsumer Services

Read full story

NEWS

negative

Business Standard - Markets 11d ago

Onesource Industries & Ventures reports standalone net loss of Rs 1.99 crore in the March 2026 quarter

Sales rise 2.20% to Rs 19.02 crore

ONESOURCEHealthcare

Read full story

ONESOURCE

Price History

Investment Checklist

Technical Analysis

Technical Analysis

Trend

Price Action

Support & Resistance Levels

Volume Analysis

Stop Loss Levels

Fixed Risk

Technical Levels

Financials

Financial Analysis

Peer Comparison

Peer Comparison

Corporate Information

Large Deals

Announcements

Board Meetings

Corporate Events

Shareholding Pattern

Shareholding Pattern

Current Distribution

Trend (Last 5 Qtrs)

Latest News

News for ONESOURCE

Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift

AI-led global earnings pressure India; opportunities in power, pharma: Conrad Saldanha

Onesource Industries & Ventures reports standalone net loss of Rs 1.99 crore in the March 2026 quarter

Frequently Asked Questions

What is the current share price of Onesource Specialty Pharma Limited (ONESOURCE)?

What is the technical sentiment for ONESOURCE stock?

What is the 52-week high and low for Onesource Specialty Pharma Limited?

Which sector does Onesource Specialty Pharma Limited belong to?

What is the market capitalization of ONESOURCE?